Medicine
Mycapssa 20 mg delayed-release capsule
Mycapssa 20 mg delayed-release capsule is a prescription medicine containing Octreotide for oral use, marketed by Chiesi, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Until first use, store unopened wallets of MYCAPSSA refrigerated at 2° to 8°C…
Key facts
- Active ingredient (INN)
- Octreotide
- Brand
- Mycapssa
- Strength
- 20 mg
- Dosage form
- Delayed-release capsule
- Route
- Oral
- Packs
- 4 blister pack
- Marketing authorisation holder
- Chiesi
- Manufacturers
- ChiesiAmryt Pharmaceuticals Designated Activity
- Origin register
- US FDA, United States
- Storage
- Until first use, store unopened wallets of MYCAPSSA refrigerated at 2° to 8°C (36° to 46°F). Do not freeze. After first use, opened wallets may be stored at 20° to 25°C (68° to 77°F) for up to 1 month.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H01CB02 Octreotide
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 July 2020
- Identifiers
- RxCUI 2380611, 2380617DailyMed set ID 58d80bc6-bdfb-4908-93e7-aace447c8d1a, 62a5e1eb-b48e-4ea6-8781-f75e490b17e4NDC 10122-550, 69880-120Application NDA208232
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 blister pack in 1 dose pack / 7 capsule, delayed release in 1 blister pack | 10122-550-28 | Chiesi | 6 July 2020 |
| 4 blister pack in 1 dose pack / 7 capsule, delayed release in 1 blister pack | 69880-120-28 | Amryt Pharmaceuticals Designated Activity | 6 July 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Octreotide
Clinical summary
Octreotide is a somatostatin analog indicated to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1, somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection. MedsAcross supplies Octreotide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about OctreotideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Sandostatin prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Oczyesa: European public assessment report (EPAR) · European Medicines Agency
Need Mycapssa 20 mg delayed-release capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.